Search

Your search keyword '"E. Bompas"' showing total 2 results
Start Over Author "E. Bompas" Region europe
2 results on '"E. Bompas"'

1. Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network.

Author

Bompas E, Martin V, Meniai F, Toulmonde M, Marec-Berard P, Claude L, Ducimetiere F, Chargari C, Minard-Colin V, Corradini N, Laurence V, Piperno-Neumann S, Defachelles AS, Bernier V, Italiano A, Orbach D, Blay JY, Gaspar N, and Berlanga P

Subjects
Adolescent, Adult, Age Factors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Child, Community Networks organization & administration, Community Networks supply & distribution, Europe, France, Humans, International Cooperation, Lung Neoplasms radiotherapy, Lung Neoplasms secondary, Maintenance Chemotherapy, Medical Oncology, Middle Aged, Neoplasm Recurrence, Local radiotherapy, Neoplasms, Germ Cell and Embryonal therapy, Osteosarcoma therapy, Radiotherapy Dosage, Randomized Controlled Trials as Topic, Rhabdomyosarcoma therapy, Sarcoma, Alveolar Soft Part therapy, Sarcoma, Ewing therapy, Societies, Medical, Young Adult, Bone Neoplasms therapy, Cancer Care Facilities organization & administration, Cancer Care Facilities supply & distribution, Patient Care Team organization & administration, Sarcoma therapy, Soft Tissue Neoplasms therapy
Abstract

Sarcomas are a rare heterogeneous group of malignant neoplasms that can arise in almost any anatomic site and any age. Close collaboration among adult and pediatric cancer specialists in the management of these tumors is of foremost importance. In this review, we present the current multidisciplinary organization in care of patients with sarcoma in France and we review the main advances made in the last decades in systemic and radiotherapy treatment in the main sarcoma types diagnosed in children, adolescents and young adults (AYA), thanks to the international collaboration., (Copyright © 2020. Published by Elsevier Masson SAS.)

Published
2021
Full Text
View/download PDF

2. Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.

Author

Verspoor FGM, Mastboom MJL, Hannink G, Maki RG, Wagner A, Bompas E, Desai J, Italiano A, Seddon BM, van der Graaf WTA, Blay JY, Brahmi M, Eberst L, Stacchiotti S, Mir O, van de Sande MAJ, Gelderblom H, and Cassier PA

Subjects
Adult, Australia, Disease Progression, Disease-Free Survival, Europe, Female, Humans, Middle Aged, Neoplasm Metastasis, Receptors, Colony-Stimulating Factor antagonists & inhibitors, Retrospective Studies, Treatment Outcome, United States, Antineoplastic Agents therapeutic use, Giant Cell Tumor of Tendon Sheath drug therapy, Imatinib Mesylate therapeutic use
Abstract

Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study investigated the long term effects of IM in TGCT. We conducted an international multi-institutional retrospective study to assess the activity of IM: data was collected anonymously from individual patients with locally advanced, recurrent or metastatic TGCT. Sixty-two patients from 12 institutions across Europe, Australia and the United States were identified. Four patients with metastatic TGCT progressed rapidly on IM and were excluded for further analyses. Seventeen of 58 evaluable patients achieved complete response (CR) or partial response (PR). One- and five-year progression-free survival rates were 71% and 48%, respectively. Thirty-eight (66%) patients discontinued IM after a median of 7 (range 1-80) months. Reported adverse events in 45 (78%) patients were among other edema (48%) and fatigue (50%), mostly grade 1-2 (89%). Five patients experienced grade 3-4 toxicities. This study confirms, with additional follow-up, the efficacy of IM in TGCT. In responding cases we confirmed prolonged IM activity on TGCT symptoms even after discontinuation, but with high rates of treatment interruption and additional treatments.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results